Strike action from Thursday 27 June to Tuesday 2 July 2024

Junior doctors at The Christie will strike from 7am on Thursday 27 June until 7am on Tuesday 2 July 2024.

We are proactively contacting patients with appointments that may be affected. If you have an appointment on any of these dates, please continue to come to The Christie and our other centres as planned, unless we contact you to tell you otherwise. Please do not call to check if your appointment is still going ahead.

Skip to Content

Help us improve our website

Clinical trials in diffuse large B cell lymphoma

The list below shows The Lymphoma Group's current clinical trials open/due to open for recruitment for Diffuse large B-cell lymphoma patients.

If you would like to know how to access our trials, please see how to contact us.

  • REMoDL-A - testing acalabrutinib, in combination with R-CHOP, in people with DLBCL who have not been treated before.
  • LOTIS-5 - testing a new treatment called loncastuximab tesirine, combined with rituximab, in people with DLBCL that has not responded (refractory) or has come back (relapsed) after previous treatment
  • POLA-R-ICE - testing the combination of standard R-ICE chemotherapy with polatuzumab in people with refractory or relapsed DLBCL
  • DTP3 - testing a new medication, DTP3, in people with relapsed or refractory diffuse large B cell lymphoma (DLBCL)
  • StepPharma/STP938 - Testing STP938 in people with T-cell and B-cell lymphomas that has relapsed or is refractory


With special thanks to the following:

Lymphoma actionCRUKBloodwiseNCRI

For further information on each trial, please visit the Find a trial page on Lymphoma Action’s website.

Last updated: October 2023